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6.4 g/kg glycosylated rhG-CSF) according to the WHO international potency standard for G-CSF. 4 Even the total costs in the two groups were not different in this study.
As a conclusion, we still do not find reason to conduct further randomised trials, but it is of course open to anyone who may feel the need to do so.
We regret that a typographical error in the manuscript has escaped our notice. We appreciate Miclea's efforts in
Post-transplant Epstein-Barr virus-associated meningoencephalitis and lymphoid interstitial pneumonitis
Post-transplant-associated Epstein-Barr virus (EBV) disease following allogeneic BMT usually presents as masses secondary to B cell proliferation. [1] [2] [3] [4] We present a case of a 4-year-old female, who, following a BMT for AML using an HLA-matched, unrelated donor, T cell-replete donor graft, developed meningoencephalitis and lymphoid interstitial pneumonitis (LIP) associated with EBV.
Pre-transplant serology showed the patient to be EBV seronegative. The clinical course was unremarkable until day +50 post BMT when she acutely developed lethargy, severe ataxia and truncal weakness. She was afebrile, and had no appreciable hepatosplenomegaly or adenopathy. The CsA level was 2688 g/l (whole blood, polyclonal antibody method) and CsA was discontinued. An MRI scan of the brain demonstrated patchy meningeal enhancement, diffuse cerebral atrophy and basal ganglia gliosis. Blood, urine and cerebral spinal fluid (CSF) cultures were negative. The CSF showed 2 RBC and 9 WBC (100% lymphocytes and monocytes). PCR of the CSF and peripheral blood were positive for EBV. CT scans of the chest and abdomen revealed no abnormalities in the abdomen. Although she had no respiratory symptoms or oxygen requirement diffuse bilateral interstitial infiltrates consistent with lymphoid interstitial pneumonitis (LIP) were found on the chest CT scan. In addition to discontinuation of the CsA, interferon-␣ (IFN) at 10 x 10 6 U/m 2 subcutaneously was initiated, as discovering this error. The P value given on page 1167, first column, line three from the bottom: P = 0.46 should read P = 0.15. This error does not affect the conclusions of the study. well as intravenous acyclovir (ACV) (1500 mg/m 2 /day) and IVIG (500 mg/kg/week).
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IFN levels in serum and CSF were determined by an ELISA kit (BioSource International, Camarillo, CA, USA) as per manufacturer's protocol (sensitivity 25 pg/ml and range 0-500 pg/ml). EBV DNA levels in the peripheral blood were semi-quantitated by PCR, as previously described (sensitivity у2 copies/g of DNA). 5, 6 At presentation, EBV was detectable in the CSF (quantitation of EBV levels in the CSF was not performed due to small amounts of DNA) and the level of EBV DNA in peripheral blood was 80 copies. Two weeks after presentation, there was no change in neurologic status, and the CSF remained positive for EBV. However, a repeat chest CT scan showed resolution of the LIP, with a drop to three copies of EBV DNA in the peripheral blood. IFN levels were readily detectable in the serum (252 pg/ml), but IFN was not detectable in the CSF. The IFN dose was then decreased to 3 ϫ 10 6 U/m 2 /day. One month after presentation no objective clinical improvement was appreciated and an MRI scan showed progressive cerebral atrophy, but PCR of the CSF revealed no detectable EBV DNA. The level of IFN in the serum was 114 pg/ml, but again no IFN was detected in the CSF. Over the next few weeks, the patient began to demonstrate increased truncal tone and decreased ataxia. At 3 months following diagnosis of EBV disease, the IFN was discontinued due to liver toxicity, but she continued on ACV (500 mg/m 2 /day orally) and IVIG was changed to every 4 weeks. Over the next 6 months, she continued to demonstrate slow clinical improvement and ultimately all neurologic symptoms resolved with no residual sequelae. Follow-up MRI scans showed no evidence of meningeal enhancement, but continued to show atrophy and gliosis of the white matter. EBV DNA remained undetectable in all subsequent CSF and blood samples.
This case illustrates the potential diverse presentations of post-transplant EBV disease. Although tissue biopsies were not obtained to definitively prove EBV presence in the lesions, the timing post transplant, ie Ͻ100 days, and presence of EBV DNA in the blood and CSF in a patient who was EBV seronegative prior to BMT, strongly implicate EBV as the etiologic agent for the meningoencephalitis and LIP. Although infrequently noted in post-transplant patients, both these entities have been associated with EBV in the AIDS population. [1] [2] [3] 7, 8 The role of CsA in this patient's neurologic symptoms is uncertain. The level of CsA was certainly high at the time of presentation, but clinical improvement followed well after discontinuation of the CsA. Additionally, the MRI findings were not typical for CsA toxicity. However, the high CsA level may have had an indirect effect by suppressing the immune response to a primary EBV infection.
In treating EBV-associated lymphoproliferative disease (LPD), withdrawal or reduction of immunosuppression is usually attempted, but often does not result in complete resolution of the disease. 1, 3 There are anecdotal reports of successful treatment with antivirals, ie acyclovir or ganciclovir, but usually this has been in conjunction with reduction or withdrawal of immunosuppression and/or IVIG. 1, 7 One could speculate that these interventions may be more efficacious in atypical presentations, such as in this patient vs more typical LPD. Successful treatment of post-transplant EBV disease has been achieved with IFN, but the precise mechanism of action is unknown. [1] [2] [3] 10 It is interesting that resolution of the LIP and clearing of EBV DNA in the peripheral blood temporally was associated with increased levels of IFN in the serum, but IFN was never detectable in the CSF, suggesting IFN does not penetrate the blood-brain barrier. It has been suggested that IFN can mediate effects in the CNS indirectly by peripherally activated effector cells and/or secreted cytokines that do penetrate the blood-brain barrier. 10, 11 Conclusions about the efficacy of IFN in this patient must be cautious. The efficacy of any particular therapeutic intervention in this case is difficult to ascertain, since ACV, IVIG and IFN were all begun at the same time the CsA was discontinued.
Semiquantitation of EBV DNA by PCR has been used to identify patients at high risk for post-transplant EBV disease and to monitor response to therapy. 4, 6, 8, 12 Although the majority of patients with post-transplant EBV disease have elevated levels of EBV DNA in the blood, this is not an absolute finding. In this patient, EBV DNA levels were not dramatically elevated, ie 80 copies/g DNA, at time of diagnosis, but radiographic resolution of the LIP correlated with the clearing of EBV DNA in the peripheral blood, and clinical improvement in CNS symptoms was not observed until EBV DNA became undetectable in the CSF.
In summary, this case illustrates the potential diverse manifestation of post-transplant EBV disease, and the potential utility of PCR in the diagnosis of disease and monitoring of response to therapy. 
